Volequin injection

18 TO 65 YEARS OLD
For the parenteral and oral dosage forms showing a bioequivalence, the same dosage can be used, usually for 7-14 days depending on severity of the disease.
Usual dosage in patients with normal renal function (creatinine clearance >80 ml/minute) is 250-500 mg once daily depending on type and severity of the infection and sensitivity of the pathogens.
It is usually possible to switch from initial intravenous treatment to the oral route after a few days, according to the condition of the patient.

65 YEARS OLD AND ABOVE
Elderly patients should receive the same dosage as normal adult patients.

PATIENTS WITH IMPAIRED HEPATIC FUNCTION
Patients with impaired hepatic function (but normal renal function) should receive the same dosage as normal adult patients.

PATIENTS WITH RENAL INSUFFICIENCY
Dosage in patients with renal insufficiency (creatinine clearance ≤50 ml/minute):
Renal clearance ≥50 ml/minute
No dosage adjustment required.

Renal clearance 20-49 ml/minute
Initial dosage: 500 mg.
Subsequent dosage: 250 mg per 24 hours.

Renal clearance 10-19 ml/minute
Initial dosage: 500 mg.
Subsequent dosage: 125 mg per 24 hours.

Hemodialysis
Initial dosage: 500 mg.
Subsequent dosage: 125 mg per 24 hours.

CAPD (Chronic Ambulatory Peritoneal Dialysis)
Initial dosage: 500 mg.
Subsequent dosage: 125 mg per 24 hours.

ADMINISTRATION
Levofloxacin hemihydrate injection should only be administered by slow intravenous infusion. The infusion time for 500 mg (100 ml) should not be less than 60 minutes and 250 mg (50 ml) should not be less than 30 minutes.

Protection from the light is not necessary during infusion time. Once the vial has been opened (rubber stopper perforated) the solution should be used immediately (within 3 hours) in order to prevent any bacterial contamination.

Levofloxacin injection is indicated when intravenous administration offers a route administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). Levofloxacin is indicated in Adults (≥18 years) in infections with susceptible microorganism, such as:
– Acute maxillary sinusitis.
– Acute bacterial exacerbations of chronic bronchitis.
– Pneumonia (community-acquired pneumonia).
– Uncomplicated skin and skin structure infections.
– Complicated urinary tract infection.
– Acute pyelonephritis.
If bacterial resistance occurs and the result of the therapy does not satisfy, the bacterial monitoring needs to be performed.